Group 1 - The company, Reap Bio (300119), announced that it will hold its fourth extraordinary general meeting of shareholders on August 25, 2025 [1] - The agenda for the meeting includes the proposal for the company and its subsidiaries to continue engaging in asset pool business and providing guarantees [1]

Group 1 - The company, Reap Bio, announced the convening of its 25th temporary board meeting on August 8, 2025, to discuss the proposal for the fourth temporary shareholders' meeting of 2025 [2] - For the year 2024, the revenue composition of Reap Bio is as follows: veterinary biological products account for 43.12%, veterinary drugs account for 33.86%, pet supply chain accounts for 20.63%, and others account for 2.38% [2]

一、担保情况概述 1、基本情况 证券代码：300119 证券简称：瑞普生物 公告编号：2025-060 瑞普生物股份有限公司 关于公司及子公司继续开展资产池业务并提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2024 年 3 月 8 日，公司第五届董事会第十二次（临时）会议及第五届监事 会第九次（临时）会议审议通过了《关于公司及子公司继续开展资产池业务并提 供担保的议案》，公司及部分分子公司与浙商银行股份有限公司天津分行（以下 简称"浙商银行天津分行"）开展总额不超过 1 亿元的资产池业务，有效期一年。 详见公司在 深 圳 证 券 交 易 所 网 站 （ http://www.szse.cn ） 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于公司及子公司继续开展资产池业务并 提供担保的公告》（公告编号：2024-010）。 为保障公司业务的连续性，盘活资产，提高流动资产的使用效率，公司及部 分分子公司，即：瑞普（天津）生物药业有限公司（以下简称"瑞普天津"）、 瑞普（保定）生物药业有限公司（以下简称" ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-061 关于召开 2025 年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2025年第四次临时股东大会 2、会议召集人：经公司第五届董事会第二十五次（临时）会议审议通过， 公司董事会决定召开2025年第四次临时股东大会。 3、会议召开的合法、合规性：本次股东大会的召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开时间： 现场会议召开时间：2025 年 8 月 25 日（星期一）14:30 瑞普生物股份有限公司 网络投票时间为： 通过深圳证券交易所交易系统进行网络投票的时间为2025年8月25日09:15- 09:25、09:30-11:30和13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2025年8月25日09:15- 15:00期间的任意时间。 5、会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方 式。 （1）现场投票：包括本人出席及通过填写 ...

第五届监事会第二十一次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十一次（临 时）会议于 2025 年 8 月 8 日在公司会议室以现场方式召开。会议通知于 2025 年 8 月 5 日以书面及网络方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由周仲华先生主持。本次会议的召集、召开 和表决程序符合《公司法》《证券法》等法律法规和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于公司及子公司继续开展资产池业务并提供担保的议案》 证券代码：300119 证券简称：瑞普生物 公告编号：2025-059 瑞普生物股份有限公司 具体内容详见公司于 2025 年 8 月 8 日披露于深圳证券交易所网站 （http://www.szse.cn）及巨潮资讯网（http://www.cninfo.com.cn）的《关于公司及 子公司继续开展资产池业务并提供担保的公告》。 表决结果：同意 3 票，反对 0 票，弃 ...

瑞普生物股份有限公司 第五届董事会第二十五次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十五次（临 时）会议于 2025 年 8 月 8 日在公司会议室以现场结合通讯表决方式召开。会议 通知于 2025 年 8 月 5 日以书面及网络方式送达全体董事。公司应出席董事 9 人， 实际出席董事 9 人，参与表决董事 9 人（其中董事李睿、杨鶄，独立董事郭春林、 才学鹏、李娅以通讯方式参会）。本次会议由董事长李守军先生主持，公司高级 管理人员列席了会议。本次会议的召集、召开和表决程序符合《公司法》《证券 法》等法律法规和《公司章程》的规定。 证券代码：300119 证券简称：瑞普生物 公告编号：2025-058 公司参与资产池业务主体有：分公司、全资子公司及控股子公司，具有较为 充足的偿还债务能力，公司能够对其实施有效的业务、资金管理和风险控制，对 其提供担保不会影响公司主营业务的正常开展。控股子公司龙翔药业提供反担保， 此次资产池业务的财务风险处于公司可控的范 ...

证券日报网讯瑞普生物8月6日在互动平台回答投资者提问时表示，公司持续投入动物创新药研发，至今 已获得116项新兽药注册证书（其中，国际首创一类新兽药8项），位于行业领先水平。公司聚焦兽用药 物新晶体、化合物新结构、多联多价疫苗、基因工程疫苗等领域深耕，致力于解决行业关键技术瓶颈， 铸就领先技术优势。 （文章来源：证券日报） ...

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1][8]. Core Viewpoints - The report highlights a long-term revaluation opportunity for the pig industry, indicating that while pig prices are experiencing fluctuations, there is still downward pressure. The industry is expected to transition towards a self-regulatory and stable phase, benefiting leading companies such as Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture [4][14]. - The poultry sector is currently facing low prices, but there are signs of marginal improvement in the cycle, with recommendations for companies like Shennong Development and Lihua Stock [5][24]. - The animal health sector is anticipated to see performance recovery and investment opportunities in pet medical services, with a focus on companies like Kexin Biological and Ruipuhua [6][34]. - The planting sector is experiencing a decline in the pig-to-grain price ratio, with ongoing commercialization of genetically modified seeds benefiting early adopters [7][37]. - The feed sector is witnessing price fluctuations, with recommendations for Haida Group and attention to He Feng Stock [7][42]. - The pet economy is thriving, with domestic brands gaining strength, and the report recommends companies in the pet food sector such as Guibao Pet and Zhongchong Stock [7][51]. Summary by Sections Pig Industry - The average price of pigs is currently around 14.08 yuan/kg, with fluctuations noted [14]. - The number of breeding sows has increased slightly, indicating a stable supply [14]. - Key recommendations include Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture, with a suggestion to pay attention to Dekang Agriculture [4][14]. Poultry Industry - The price of white feather chicken is low, with a focus on potential marginal improvements in the cycle [5][23]. - The report notes a significant update in the breeding stock, with a mix of imported and self-bred varieties [5][24]. - Recommended companies include Shennong Development and Lihua Stock [5][24]. Animal Health - The report anticipates continued recovery in animal health companies' performance, supported by stable profits in the pig farming sector [6][34]. - The approval of mRNA vaccines for veterinary use marks a significant technological advancement [6][34]. - Recommended companies include Kexin Biological and Ruipuhua, with additional attention to Huisheng Biological and Jinhai Biological [6][34]. Planting Sector - The pig-to-grain price ratio has decreased, with ongoing commercialization of genetically modified seeds [7][37]. - Recommendations include Suqian Agricultural Development and Longping High-Tech [7][37]. Feed Sector - Feed prices are experiencing fluctuations, with specific prices noted for different types of feed [7][42]. - The report suggests that the feed industry is likely to see increased concentration, recommending Haida Group and monitoring He Feng Stock [7][42]. Pet Industry - The pet market is growing, with a significant increase in consumption and brand development [7][51]. - Recommendations include Guibao Pet, Zhongchong Stock, and Peidi Stock in the pet food sector, as well as Ruipuhua in the pet medical sector [7][51].

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]